All FGFR4 reagents are produced in house and quality controlled, including 14 FGFR4 Antibody, 2 FGFR4 ELISA, 24 FGFR4 Gene, 9 FGFR4 Lysate, 9 FGFR4 Protein, 3 FGFR4 qPCR. All FGFR4 reagents are ready to use.
Recombinant FGFR4 proteins are expressed by HEK293 Cells with fusion tags as C-human IgG1-Fc, C-human IgG1-Fc & His, C-His.
FGFR4antibodies are validated with different applications, which are ELISA, IHC-P, WB, ELISA(Cap).
FGFR4cDNA clones are full length sequence confirmed and expression validated. There are 13 kinds of tags for each FGFR4 of different species, especially GFP tag, OFP tag, FLAG tag and so on. There are three kinds of vectors for choice, cloning vector, expression vector and lentivrial expression vector.
FGFR4ELISA Kit are quality controlled by 8 internation QC standard which guarantee every ELISA Kit with high quality.
Fibroblast growth factor receptor 4 (FGFR4) also known as CD334 antigen or tyrosine kinase related to fibroblast growth factor receptor, is a member of the fibroblast growth factor receptor family, where amino acid sequence is highly conserved between members and throughout evolution. FGFR family members differ from one another in their ligand affinities and tissue distribution. A full-length representative protein would consist of an extracellular region, composed of three immunoglobulin-like domains, a single hydrophobic membrane-spanning segment and a cytoplasmic tyrosine kinase domain. The extracellular portion of FGFR4/CD334 interacts with fibroblast growth factors, setting in motion a cascade of downstream signals, ultimately influencing mitogenesis and differentiation. FGFR4/CD334 preferentially binds acidic fibroblast growth factor and, although its specific function is unknown, it is overexpressed in gynecological tumor samples, suggesting a role in breast and ovarian tumorigenesis. FGFR4/CD334 signaling is down-regulated by receptor internalization and degradation; MMP14 promotes internalization and degradation of FGFR4/CD334. Mutations in FGFR4/CD334 lead to constitutive kinase activation or impair normal FGFR4 inactivation lead to aberrant signaling.